Technology Offers Site map description
Biomedical Research Center Sant Pau (IIB) posted this:An in vitro methodology that offers the possibility to correct a genetic mutation through the use of advanced therapiesThe invention is an in vitro method that allows the recovery of F5 gene expression by the use of CRISPR/Cas9, a genetic modification tool of high precision. The access to exploit this methodology will benefit the licensee the possibility to perform cellular and genetic therapy to treat and reverse the disease.
Peter Mogyorosi posted this:An Innovative Technology to Effectively Utilize and Recycle Sewage SludgeOur partner, a Hungarian company developed a patented technology that provides a solution for transforming municipal sewage sludge into solid fuel (Solid Recovered Fuel - SRF), which also enables sewage plants to achieve significant cost savings.
CEO at Laser Consult Ltd.
- Fabian BelinLuxembourg Institute of Science and Technology (LIST)Fabian Belin
Partnerships Development & IP Valorization at Luxembourg Institute of Science and Technology (LIST)
Fabian Belin posted this:An interactive software tool to deal with missing values (gap filling) in hydrological time series for water managementgapIT is a JAVA-based software package that automatically calculates missing data using different data-infilling techniques, using hydrological discharge data series measures at gauging stations as input. Donor stations are automatically selected based on Dynamic Time Warping, geographical proximity and upstream/downstream relationships among stations. For each gap, the tool computes several flow estimates through various data-infilling techniques, including interpolation, multiple regression, regression trees and neural networks. The interactive visual application allows the user to select different donor station(s) than those automatically selected. The results are validated by randomly creating artificial gaps of different lengths and positions along the entire records. Using the Root Mean Squared Error and the Nash-Sutcliffe coefficient as performance measures, the method is evaluated based on a comparison with the actual measured discharge values.
Partnerships Development & IP Valorization at Luxembourg Institute of Science and Technology (LIST)
Yeda posted this:An Off-Line Image Search EngineAlthough images search engines are available online, offline networks and databases (in governmental offices, banks, etc.) require an efficient and reliable image search engine. Prof. Michal Irani and her team developed a method for Visual Inference of a collection of images, which builds upon collaboration between the images. This algorithm could implement inside offline networks without relying on external databases.
Fundació URV posted this:An open-source scalable Personal Cloud that can adapt to the necessities of organizations.StackSync is an Open Source Personal Cloud that takes care of your real needs and provides a cloud storage solution with scalability, security and privacy awareness. StackSync fits perfectly in any kind of organization (e.g., Enterprise, SME, Government, Educational) offering adaptable cloud storage: private, hybrid or public. For more information: http://youtu.be/Z76poRg92hI http://stacksync.org/
- SUSANA CÁMARA DECIMAVILLAUNIVERSIDAD DE BURGOSSUSANA CÁMARA DECIMAVILLA
CEO at UNIVERSIDAD DE BURGOS
SUSANA CÁMARA DECIMAVILLA posted this:Anaerobic treatment of biodegradable waste liquidsBioreactor formed by two connected closed tanks (anaerobic digestion tank and filtration tank) for the anaerobic treatment of complex wastewater with biogas production. A support material is used, in a non-arranged way, increasing the active biomass accumulation capacity and allowing downwards flow in the digestion tank.
CEO at UNIVERSIDAD DE BURGOS
Universidad de Alcalá-OTRI posted this:Analysis and heuristic optimization software system for wind farm design.The utilization of technologies of soft computing has been vaguely applied to the optimization of the design of wind farms, and only with a limited set of parameters. Gheode group has developed a series of algorithms that consider in a much more realistic way the designing of parks, having in addition a great versatility to incorporate improvements or made-to-measure expansions for every client in particular.
CSIC - Consejo Superior de Investigaciones Científicas posted this:Andrographolide derivatives for its use as treatment for inflammatory diseasesAndrographolide derivatives for its use as treatment for inflammatory diseases related to cytokine storm. CSIC, the Polytechnic University of Valencia, the University of Navarra and the Medical Applied Research Foundation have developed semi-synthetic derivatives of andrographolide, a plant-derived product, very useful for the treatment of inflammatory diseases related to a massive cytokine release. These new compounds show a secure and specific way to control the inflammation, that can be caused by a viral infection, as COVID-19, a bacterial infection or by immunotherapy. Industrial partners are being sought to collaborate through a patent licence agreement or codevelopment. An offer for Patent Licensing or Collaboration for development
Technology Transfer Office
TTPU posted this:Anti-adhesive Biopolymer CoatingResearchers have developed an anti-adhesive coating based on a polymer naturally and sustainable produced by a marine bacterium. This coating prevents the bacterial adhesion and the subsequent biofilm formation that usually leads to host bacterial infections difficult to eradicate and control with the antibiotics currently in use, namely in hospital environments. This coating can be applied in a cost effective way to a broad range of materials through the application of a universal glue.
Leading Biology posted this:Anti-GPCR Antibody ProductionWith rich experience in antibody discovery and membrane protein studies, experts from Leading Biology have launched a membrane protein antibody development platform. We provide a one-stop service of anti-GPCR membrane protein antibody discovery service against a variety of GPCR targets now.
Business Development Manager at Leading Biology
Yeda posted this:Anti-QSOX1 Antibody for Treating Cancer and MetastasisCancer, and especially cancer metastasis, is a leading cause of death worldwide. Research in recent years highlighted the importance of the extracellular matrix (ECM) surrounding the tumor in cancer progression metastasis formation. Therefore, many attempts currently address the unmet need to target enzymes that remodel the ECM to treat cancer. The current technology is a monoclonal antibody that specifically inhibits QSOX1, an enzyme that remodels the ECM and is up-regulated in several cancers. The antibody effectively inhibited tumor progression and metastasis formation in several mouse models, especially when combined with chemotherapies. The antibody potentially offers a generalized treatment for several cancer types as a single agent or in combination with standard of care chemotherapies.
Javier Montiel Bonmatí posted this:Antibacterial alternative to antibiotics, with high specificity against Escherichia coliThe "Molecular Microbiology" research group at the University of Alicante has modified several phage proteins (Poll-N and UK-C) that have high specificity against Escherichia coli (E. coli), but not against other Gram-negative (G-) bacteria. For these reasons, their use as a specific antimicrobial against E. coli is potentially interesting, especially in the case of contaminated food, cosmetics or water. It would also be useful in the treatment of diseases (infections) caused by E. coli. The presence of a histidine tail attached to the phage proteins not only facilitates their purification but also improves lysis efficiency without the need of cell permeabilization treatments. Companies interested in the commercial exploitation of the technology through license agreements and/or technical cooperation are sought.
Universidad de Alicante
CSIC - Consejo Superior de Investigaciones Científicas posted this:Antibiotics to treat diseases caused by HelicobacterCSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing
CNIC (TTO) posted this:Antibodies for the diagnosis and/or treatment of atherosclerosisNovel atherosclerosis biomarkers are in need to improve the strategies for diagnosis and prognosis of cardiovascular disease. CNIC and DKFZ researchers have discovered 18 novel antibodies that show reactivity against the atherosclerotic plaque, which can thus be potentially used for the diagnosis of this disease. Moreover, the use of one such antibody, A12, delays the progression of atherosclerosis and reduces the level of free circulating cholesterol and LDL.
Technology Transfer Office at Spanish National Center for Cardiovascular Research (CNIC)
CSIC - Consejo Superior de Investigaciones Científicas posted this:Antibodies to measure residual levels of mycotoxin ochratoxin A in foodCSIC and the University of Valencia have developed antibodies capable of determining ochratoxin A in food and ensure compliance with legislation on food products regarding the presence of this mycotoxin. Antibodies have been generated using novel functionalized derivatives of ochratoxin A. These immunoreagents have shown their efficacy in both direct and indirect competitive ELISA to detect concentrations close to parts per trillion. We are looking for companies interested in patent licensing for the development of fast, sensitive and portable kits for the analysis of ochratoxin A in foods and beverages based on these antibodies. The license of the patent is offered Effective, fast and accurate detection Ochratoxin A has a higher incidence in cereals, wine, juices and coffee One of the most harmful and frequent mycotoxins in food is ochratoxin A. Its presence is a real problem for human health due to its toxicity, and it causes significant economic losses to various productive sectors. The main fungi producing ochratoxin A belongs to the genera Penicillium and Aspergillus, and the products with the highest incidence are cereals, wine, juices and coffee. The small concentrations at which this potent toxin is usually found commonly require the use of sophisticated chromatographic methods. An alternative is the generation of antibodies against ochratoxin A with superior performance to the existing ones that allow this toxin being recognized with high affinity and specificity. These immunoreagents can be easily implemented in various analytical platforms, from the simplest, such as competitive ELISAs and immunochromatographic strips, to more complex, like chips or biosensors of different types, which allows us to simultaneously analyze a large number of samples in low-resource settings such as warehouses, cellars and even farmlands. Main applications and advantages Ochratoxin A derivatives functionalized at new positions have been synthesized that faithfully preserve the structure and characteristics of this potent mycotoxin. These new compounds have proven to be extremely efficient as haptens to generate antibodies capable of recognizing ochratoxin A with an affinity and selectivity not previously described. Immunoassays developed using these immunoreagents have been shown to be very sensitive, allowing analysis of ochratoxin A at levels close to 10 parts per trillion. These new methods are faster than instrumental procedures, especially when analyzing complex samples such as wine and coffee. The generated immunoreagents are easily adaptable to portable methods, such as ELISA kits or immunochromatographic strips. Patent status Prioriy patent application filed suitable for international extension For more information contact with: Mª Jesus Añón Marín Instituto de Agroquímica y Tecnología de Alimentos Consejo Superior de Investigaciones Científicas (CSIC) Tel.: +34 963900022 E-mail: firstname.lastname@example.org
Yeda posted this:Antibody Based Therapy to Treat Cancer and GI Related DiseasesA novel therapeutic antibody against MMP-7, with exceptional specificity, for the treatment of aggressive cancers. Although early programs targeting MMPs (matrix metalloproteins) were largely unsuccessful due to adverse side effects, they remain a viable and highly desirable therapeutic target. The main obstacle in the attempts to target MMPs is the ability to selectively target individual MMPs. The present invention provides highly selective targeted therapy against MMP-7, which is strongly associated with aspects of cancer development such as angiogenesis and metastasis. In a further development of their previous groundbreaking synthetic metal-protein mimicry molecules, researchers from Prof. Irit Sagi’s lab generated an antibody which exhibits exceptional degree of specificity towards MMP-7 over other MMPs. The present technology offers an opportunity to re-introduce improved MMP-targeting agents to the cancer therapeutics market, in particular aggressive cancers that face a major unmet medical need.
ALL Chemistry Inc. posted this:Antibody Drug Conjugates (ADCs)At ALL Chemistry Inc. we are dedicated to providing our customers with the highest quality Antibody-drug Conjugates technology. From our passionate customer service staff to our cutting edge technology, we guarantee that no project is too great or too small. So if you're looking for an experienced and reliable provider of Antibody-drug Conjugates technology, we at ALL Chemistry Inc. are here to help!
Universidad de Alcalá-OTRI posted this:Anticancer activity of Ru (II) Arene complexes with oxime ligands.Spanish research group from the department of Inorganic Chemistry the University of Alcala, together with a Moroccan research group from the University of Abdelmalek Essaadi, have developed a process to synthesize metal complexes with anticancer properties, which can be used for cancer treatment and prevention. The group is looking for companies working in the pharmaceutical and biomedical sector to achieve license, collaborative or commercial agreements with technical assistance.
Universidad Andres Bello posted this:Antidepressant targeting AstrocytesA fast-acting antidepressant candidate whose pharmacological target is not a neuron receptor but an astrocyte channel. The technology is based on small molecules that modulate specific astrocyte channels showing antidepressive effects.
Rui Manuel Silva posted this:Antimalarial Agent, Methods and Uses ThereofThe present disclosure relates to compounds and compositions for the treatment of malarian diseases. The compounds comprise a class of halogenated alkyl-aromatic secondary metabolites, including hierridic C, or pharmaceutically acceptable salts, esters, solvates or prodrugs thereof. The compounds comprise a halogen; C1-C6 alkyl, H, COCH3, COH, CO-alkyl, or CO-aryl; and a C3-C30 alkyl. In at least one embodiment, the compound is 3-chloro-4,6-dimethoxy-2-pentadecylphenol. The present disclosure also relates to methods of obtain the compounds from a solution comprising a cyanobacterium.
Innovation Manager at NOVA University Lisbon
Universidad de Alcalá-OTRI posted this:Antimicrobial electrospun fiber membrane with retention and controlled release capacity of active substancesResearchers from the Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering of the University of Alcalá in collaboration with researchers from the Department of Chemistry and Physics of the University of Almería, presents a procedure for the manufacture of active membranes based on submicron fibers combining an antimicrobial action with the ability to retain apolar contaminants in aqueous solution. The membranes are produced by an electrospinning process in aqueous solution from mixtures of water soluble polyacids and polyols, which are subsequently stabilized by a thermal curing process and post-functionalized by the incorporation of amino-terminated dendrimers by a grafting process using a coupling agent. The material can be applied to the treatment of drinking water, to the regeneration of waste water, to the treatment of process waters and also to the controlled release of active substances, such as drugs, food preservatives, etc. The group seeks companies from the pharmaceutical, food, material technology and environmental sectors to sign technical cooperation agreements, commercial agreement with technical assistance and patent licensing agreements.
Simona Rataj posted this:Antiviral and antibacterial textiles functionalized with natural biologically active dyeThe University of Ljubljana developed functionalized coloured textiles with antiviral and antibacterial properties based on emodin and its derivatives.
Alliance Manager at University of Ljubljana
Iker García posted this:AONIR PLATFORM, for in line and real-time production characterization based on NIRS technology.AONIR is our system based on NIR spectroscopy, for inline monitoring of processes in the food and pharmaceutical industry. It allows real-time quality control of the entire production process, from the evaluation of raw materials to the final product. This monitoring, in addition to homogenising production and increasing the quality of the final product, achieves more efficient and sustainable production.
CEO at AOTECH
IBIMA-Plataforma Bionand posted this:Aortic aneurysm treatment deviceA new improved device for the treatment of aortic aneurysm, which solves the surgical problems of current alternatives. -Universality, it can be used in any anatomy. -It has a lower learning curve, as the same system can be used for all patients. Ease of use. -Speed, it is not necessary to make a customized stent for each patient, thus reducing the waiting time for the surgery to be performed. -Thanks to the smaller diameter, the implantation procedure could be performed under local anesthesia and by arterial puncture, and used in the most unfavorable anatomies.
- Germans Trias i Pujol Health Sciences Research InstituteGermans Trias i Pujol Health Sciences Research InstituteGermans Trias i Pujol Health Sciences Research Institute
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Apotransferrin to treat strokeOur group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes). Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
- UNIVERSIDAD DE BURGOSUNIVERSIDAD DE BURGOSUNIVERSIDAD DE BURGOS
Technology Transfer Office